PULM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PULM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Pulmatrix's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $8.95 Mil. Pulmatrix's Total Assets for the quarter that ended in Dec. 2024 was $9.94 Mil. Therefore, Pulmatrix's Equity to Asset Ratio for the quarter that ended in Dec. 2024 was 0.90.
The historical rank and industry rank for Pulmatrix's Equity-to-Asset or its related term are showing as below:
During the past 13 years, the highest Equity to Asset Ratio of Pulmatrix was 0.94. The lowest was 0.31. And the median was 0.70.
The historical data trend for Pulmatrix's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pulmatrix Annual Data | |||||||||||||||||||||
Trend | Mar15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Equity-to-Asset | Get a 7-Day Free Trial |
![]() |
![]() |
0.61 | 0.81 | 0.76 | 0.53 | 0.90 |
Pulmatrix Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Equity-to-Asset | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
0.53 | 0.63 | 0.84 | 0.95 | 0.90 |
For the Biotechnology subindustry, Pulmatrix's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Pulmatrix's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Pulmatrix's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Pulmatrix's Equity to Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as
Equity to Asset (A: Dec. 2024 ) | = | Total Stockholders Equity | / | Total Assets |
= | 8.947 | / | 9.943 | |
= | 0.90 |
Pulmatrix's Equity to Asset Ratio for the quarter that ended in Dec. 2024 is calculated as
Equity to Asset (Q: Dec. 2024 ) | = | Total Stockholders Equity | / | Total Assets |
= | 8.947 | / | 9.943 | |
= | 0.90 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pulmatrix (NAS:PULM) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Thank you for viewing the detailed overview of Pulmatrix's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Peter Ludlum | officer: Interim CFO | 20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501 |
Margaret Wasilewski | officer: Chief Medical Officer | C/O PULMATRIX, INC., 99 HAYDEN AVENUE, SUITE 390, LEXINGTON MA 02421 |
Anand Varadan | director | C/O CHIASMA, INC., 60 WELLS AVENUE, NEWTON MA 02459 |
Todd Bazemore | director | C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803 |
Christopher Cabell | director | C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
Michelle Siegert | officer: Vice President, Finance | 99 HAYDEN AVENUE, SUITE 390, LEXINGTON MA 02421 |
Richard P. Batycky | director | C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
Robert Nelsen | other: Former 10% owner | 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
Polaris Venture Partners Founders' Fund V, L.p. | 10 percent owner | ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210 |
Polaris Venture Partners Entrepreneurs' Fund V, L.p. | 10 percent owner | ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210 |
Polaris Venture Partners Special Founders' Fund V, L.p. | 10 percent owner | ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210 |
Polaris Venture Partners V, L.p. | 10 percent owner | ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210 |
Polaris Venture Management Co. V, L.l.c. | 10 percent owner | ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210 |
Jonathan A Flint | 10 percent owner | 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02451 |
Polaris Venture Management Co Iv Llc | 10 percent owner | ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210 |
From GuruFocus
By PRNewswire PRNewswire • 02-06-2023
By PRNewswire • 08-10-2023
By PRNewswire PRNewswire • 05-02-2023
By PRNewswire • 05-15-2024
By PRNewswire • 03-28-2024
By PRNewswire PRNewswire • 05-24-2023
By Marketwired • 11-14-2024
By PRNewswire • 07-11-2023
By Business Wire • 02-19-2025
By Business Wire • 11-14-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.